Literature DB >> 11137927

Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis.

P López-Beret 1, A Orgaz, J Fontcuberta, M Doblas, A Martinez, G Lozano, A Romero.   

Abstract

PURPOSE: The purpose of this study was to evaluate whether low molecular weight heparin (LMWH) could be equal or more effective than conventional oral anticoagulants (OAs) in the long-term treatment of deep venous thrombosis (DVT).
METHODS: One hundred fifty-eight patients with symptomatic DVT of the lower limbs confirmed by means of duplex ultrasound scan were randomized to receive 3 to 6 months' treatment with nadroparine calcium or acenocoumarol. Quantitative and qualitative duplex scan scoring systems were used to study the evolution of thrombosis in both groups at 1, 3, 6, and 12 months.
RESULTS: During the 12-month surveillance period, two (2.5%) of the 81 patients who received LMWH and seven (9%) of the 77 patients who received OAs had recurrence of venous thrombosis (not significant). In the LMWH group no cases of major bleeding were found, and four cases (5.2%) occurred in the OA group (not significant). The mortality rate was nine (11.1%) in the LMWH group and 7.8% in the OA group (not significant). The quantitative mean duplex scan score decreased in both groups during the follow-up and had statistical significance after long-term LMWH treatment on iliofemoral DVT (1, 3, 6, and 12 months), femoropopliteal DVT (1-3 months), and infrapopliteal DVT (first month). Duplex scan evaluation showed that the rate of venous recanalization significantly increased in the common femoral vein at 6 and at 12 months and during each point of follow-up in the superficial and popliteal veins in the LMWH group. Reflux was significantly less frequent in communicating veins after LMWH treatment (17.9% vs 32.2% in the OA group). The reflux rates in the superficial (22.4% in the LMWH group, 30.6% in OA group) and deep (13.4% vs 17.7%) venous system showed no significant differences between groups.
CONCLUSIONS: The unmonitored subcutaneous administration of nadroparine in fixed daily doses was more effective than oral acenocoumarol with laboratory control adjustment in achieving recanalization of leg thrombi. With nadroparine, there was less late valvular communicating vein insufficiency, and it was at least as efficacious and safe as oral anticoagulants after long-term administration. These results suggest that LMWHs may therefore represent a real therapeutic advance in the long-term management of DVT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11137927     DOI: 10.1067/mva.2001.109336

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  17 in total

1.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Iliac vein stenting for chronic venous insufficiency.

Authors:  Firas F Mussa; Eric K Peden; Wei Zhou; Peter H Lin; Alan B Lumsden; Ruth L Bush
Journal:  Tex Heart Inst J       Date:  2007

Review 3.  Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.

Authors:  Alina Andras; Adriano Sala Tenna; Marlene Stewart
Journal:  Cochrane Database Syst Rev       Date:  2017-07-24

Review 4.  Treating venous thromboembolism in patients with cancer.

Authors:  Caroline Piatek; Casey L O'Connell; Howard A Liebman
Journal:  Expert Rev Hematol       Date:  2012-04       Impact factor: 2.929

Review 5.  Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.

Authors:  A Franco-Moreno; L Cabezón-Gutiérrez; M Palka-Kotlowsa; M Villamayor-Delgado; M García-Navarro
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

Review 6.  Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy.

Authors:  Nick van Es; Suzanne M Bleker; Ineke T Wilts; Ettore Porreca; Marcello Di Nisio
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

7.  Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

Authors:  Vincenza Snow; Amir Qaseem; Patricia Barry; E Rodney Hornbake; Jonathan E Rodnick; Timothy Tobolic; Belinda Ireland; Jodi Segal; Eric Bass; Kevin B Weiss; Lee Green; Douglas K Owens
Journal:  Ann Fam Med       Date:  2007 Jan-Feb       Impact factor: 5.166

8.  International pediatric thrombosis network to advance pediatric thrombosis research: Communication from the ISTH SSC subcommittee on pediatric and neonatal thrombosis and hemostasis.

Authors:  C Heleen van Ommen; Manuela Albisetti; Mohir Bhatt; Marianne Bonduel; Brian Branchford; Elizabeth Chalmers; Anthony Chan; Neil A Goldenberg; Susanne Holzhauer; Paul Monagle; Ulrike Nowak-Göttl; Shoshana Revel-Vilk; Gabriela Sciuccatie; Nongnuch Sirachainan; Christoph Male
Journal:  J Thromb Haemost       Date:  2021-04       Impact factor: 5.824

Review 9.  Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.

Authors:  Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Charbel F Matar; Irene Terrenato; Francesca Sperati; Maddalena Barba; Victor Ed Yosuico; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-06-19

Review 10.  Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.

Authors:  Petra M G Erkens; Hugo ten Cate; Harry R Büller; Martin H Prins
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.